Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease-Reference-Cited by-同舟云学术

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

Published:2010-08-30 Issue:21 Volume:31 Page:2601-2613
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:European Heart Journal

Author:

Goto S.,Ogawa H.,Takeuchi M.,Flather M. D.,Bhatt D. L.,

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/31/21/2601/7111133/ehq320.pdf

Reference30 articles.

1. Trends in the Incidence, Mortality, and Survival Rate of Cardiovascular Disease in a Japanese Community

2. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis

3. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis

4. Prevalence, Awareness and Treatment of Cardiovascular Risk Factors in Patients at High Risk of Atherothrombosis in Japan Results From Domestic Baseline Data of the REduction of Atherotherombosis for Continued Health (REACH) Registry

5. Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting biased signaling by PAR1: Function and molecular mechanism of parmodulins;Blood;2023-03-23

2. Co-administration of indacaterol and tiotropium bromide for the treatment of chronic obstructive pulmonary disease and bronchiectasis, and effect on IL-8 and CRP levels;Tropical Journal of Pharmaceutical Research;2023-02-05

3. Antithrombotic therapy in cardilogy—systemical improvement of the standard of care for patient population to personalized medicine—;Japanese Journal of Thrombosis and Hemostasis;2023

4. Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs;Pharmaceuticals;2022-12-09

5. Oral Antiplatelet Agents in Percutaneous Coronary Intervention;Interventional Cardiology;2022-05-06